Partikula

Partikula develops nanoparticle drug delivery technology for treatment of cancer.

We at Partikula utilize our proprietary chemical engineering technologies to develop compounds that specifically and directly target mitochondria, from the outer mitochondrial membrane to the mitochondrial matrix and areas in between. By utilizing our technologies we can now access a large number of important and in some cases well-studies targets that until now have been difficult to target with traditional therapies. Our initial clinical focus is in oncology although we do have programs in earlier stages of development in the areas of neurodegenerative, cardiovascular and orphan mitochondrial disease.